We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celltrion’s Remicade Biosimilar Gets Adcomm Backing for 6 Indications
Celltrion’s Remicade Biosimilar Gets Adcomm Backing for 6 Indications
An FDA advisory committee gave South Korea’s Celltrion’s biosimilar candidate for Remicade a strong show of support Feb. 9, backing its approval for six indications.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor